Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9257276 | 1.00 | GABRR1 (0.39) | GABRR1GRIK1ALDH1A1TSHR | |
| SCHEMBL9257272 | 1.00 | GABRR1 (0.39) | GABRR1GRIK1ALDH1A1TSHR | |
| SCHEMBL4602718 | 0.77 | GABRR1 (0.34) | GABRR1 | |
| SCHEMBL4602714 | 0.77 | GABRR1 (0.34) | GABRR1 | |
| SCHEMBL9956486 | 0.71 | GRIK1 (0.40) | GRIK1ALDH1A1TSHR | |
| SCHEMBL8518270 | 0.71 | GRIK1 (0.40) | GRIK1ALDH1A1TSHR | |
| SCHEMBL28443096 | 0.70 | GABRR1 (0.38) | GABRR1 | |
| SCHEMBL15546709 | 0.69 | — | — | |
| SCHEMBL136678 | 0.69 | — | — | |
| SCHEMBL264893 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110177454-A1 | RESIST MATERIAL AND PATTERN FORMATION METHOD USING THE RESIST MATERIAL | PANASONIC CORPORATION (JP) | 2011-07-21 | — | — | US | claimed |
| EP-4201408-B1 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA | VIFOR INT LTD (CH) | 2025-06-25 | — | — | EP | disclosed |
| EP-4201408-A1 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA | Vifor (International) Ltd. (CH) | 2023-06-28 | — | — | EP | disclosed |
| EP-3431094-B1 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA | VIFOR INT LTD (CH) | 2022-12-07 | — | — | EP | disclosed |
| US-20220000906-A1 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA | VIFOR (INTERNATIONAL) LTD. (CH) | 2022-01-06 | — | — | US | disclosed |
| US-20200289550-A1 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA | RELYPSA, INC. | 2020-09-17 | — | — | US | disclosed |
| CN-110051686-A | Composition comprising cross-linked cationic conjugated polymer | 瑞立普萨公司 | 2019-07-26 | — | — | CN | disclosed |
| EP-2365988-B2 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA | VIFOR INT LTD (CH) | 2019-07-03 | — | — | EP | disclosed |
| EP-3431094-A1 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA | Vifor Pharma Innovation Ltd. (CH) | 2019-01-23 | — | — | EP | disclosed |
| EP-2957286-B1 | COMPOSITIONS COMPRISING CROSSLINKED CATION EXCHANGE POLYMERS AND USE IN TREATING HYPERKALEMIA | VIFOR INT LTD (CH) | 2018-11-21 | — | — | EP | disclosed |
| US-20100104527-A1 | TREATING HYPERKALEMIA WITH CROSSLINKED CATION EXCHANGE POLYMERS OF IMPROVED PHYSICAL PROPERTIES | RELYPSA, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-7687991-B2 | Organic electroluminescence device | CANON KABUSHIKI KAISHA (JP) | 2010-03-30 | — | — | US | disclosed |
| WO-2010022381-A1 | TREATING HYPERKALEMIA WITH CROSSLINKED CATION EXCHANGE POLYMERS OF IMPROVED PHYSICAL PROPERTIES | RELYPSA, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010022383-A2 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA | RELYPSA, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20080280876-A1 | Novel oxadiazole compounds | ABBVIE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080012473-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE | CANON KABUSHIKI KAISHA (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1449860-A1 | NOVEL FLUOROPOLYMER, RESIST COMPOSITIONS CONTAINING THE SAME, AND NOVEL FLUOROMONOMERS | Daikin Industries, Ltd. (JP) | 2004-08-25 | — | — | EP | disclosed |
| US-5466710-A | Heterobicycloalkanes as pesticidal compounds | ROUSSEL UCLAF (FR) | 1995-11-14 | — | — | US | disclosed |
| US-5116862-A | Acetylenic trithiabicyclo(2.2.2)octanes | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-05-26 | — | — | US | disclosed |
| EP-0300797-A1 | Pesticidal compounds | ROUSSEL UCLAF (FR) | 1989-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104527-A1 | TREATING HYPERKALEMIA WITH CROSSLINKED CATION EXCHANGE POLYMERS OF IMPROVED PHYSICAL PROPERTIES | KCNJ1, KCNN3, KCNJ11 | GABRR1 1465/4885GRIK1 224/4885ALDH1A1 4815/4885 |
| US-20080280876-A1 | Novel oxadiazole compounds | S1PR3, S1PR1, S1PR2 | GABRR1 193/4885GRIK1 298/4885ALDH1A1 4044/4885 |
| US-20220000906-A1 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA | ABCB11, SLC26A3, KCNN3 | GABRR1 1132/4885GRIK1 259/4885ALDH1A1 4842/4885 |
| US-20200289550-A1 | CROSSLINKED CATION EXCHANGE POLYMERS, COMPOSITIONS AND USE IN TREATING HYPERKALEMIA | ABCB11, SLC26A3, KCNN3 | GABRR1 1132/4885GRIK1 259/4885ALDH1A1 4842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.